Novel spectacle lens design: Use of spectacle lenses may reduce the rate of progression of juvenile myopia
Study summary
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.
Eligibility
Sex
ALL
Min age
8 Years
Max age
16 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Previously a successfully completed participant in the CATHAY study (NCT05562622)
2. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day)
3. Willingness to participate in the trial for 12 months without contact lens wear or any other myopia management intervention
4. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form
Exclusion Criteria:
1\. Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate
Primary outcome measure(s)
Axial length Group I — 12 months Change in axial length from baseline to 36 months
Axial length Group II — 12 months Change in axial length from baseline to 12 months
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.